Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T47768
|
||||
Former ID |
TTDS00126
|
||||
Target Name |
Mu-type opioid receptor
|
||||
Gene Name |
OPRM1
|
||||
Synonyms |
MOR-1; MOR1A; Mu opioid receptor; OPRM1
|
||||
Target Type |
Successful
|
||||
Disease | Anesthesia [ICD9: 338; ICD10: R20.0] | ||||
Asthma [ICD10: J45] | |||||
Analgesia [ICD9: 338; ICD10: R52, G89] | |||||
Cancer pain [ICD9: 140-229, 338,780; ICD10: R52, G89] | |||||
Cough [ICD9: 786.2; ICD10: R05] | |||||
Chronic pain [ICD9: 338.2,780; ICD10: R52.1-R52.2, G89] | |||||
Constipation [ICD9: 564; ICD10: K59.0] | |||||
Diarrhea [ICD9: 787.91; ICD10: A09, K59.1] | |||||
Diabetic neuropathy [ICD9: 250, 250.6, 356.0, 356.8; ICD10: E11.40] | |||||
Diarrhea-predominant IBS [ICD9: 564.1; ICD10: K58.0] | |||||
Gastrointestinal disease [ICD10: K00-K93] | |||||
Gastrointestinal disease; Pain [ICD9:338, 356.0, 356.8, 780; ICD10: K00-K93, G64, G90.0, R52, G89] | |||||
General anesthesia [ICD9: 338; ICD10: R20.0] | |||||
Headache [ICD9: 339, 784.0; ICD10: G43-G44, R51] | |||||
Inflammatory disease [ICD9: 140-229, 147, 173, 573.3, 710-719; ICD10: C11, C44, K75.9, M00-M25] | |||||
Movement disorder [ICD10: R25] | |||||
Major depressive disorder [ICD9: 296.2, 296.3, 710.0; ICD10: F32, F33, M32] | |||||
Migraine [ICD9: 346; ICD10: G43] | |||||
Mild pain [ICD10: R52, G89] | |||||
Moderate-to-severe acute pain [ICD9: 338,780; ICD10: R52, G89] | |||||
Non-small cell lung cancer [ICD10: C33-C34] | |||||
Narcotic depression [ICD9: 304.9, 311; ICD10: F19.20, F32] | |||||
Obesity [ICD9: 278; ICD10: E66] | |||||
Opiate dependence [ICD9: 304; ICD10: F11] | |||||
Opioid-induced constipation [ICD9: 564; ICD10: K59.0] | |||||
Pain [ICD9: 338, 356.0, 356.8,780; ICD10: G64, G90.0, R52, G89] | |||||
Substance dependence [ICD10: F10-F19] | |||||
Systemic pain [ICD10: R52, G89] | |||||
Urinary incontinence [ICD9: 788.3; ICD10: N39.3, N39.4, R32] | |||||
Unspecified [ICD code not available] | |||||
Function |
Inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance. The receptor for beta-endorphin.
|
||||
BioChemical Class |
GPCR rhodopsin
|
||||
Target Validation |
T47768
|
||||
UniProt ID | |||||
Sequence |
MDSSAAPTNASNCTDALAYSSCSPAPSPGSWVNLSHLDGNLSDPCGPNRTDLGGRDSLCP
PTGSPSMITAITIMALYSIVCVVGLFGNFLVMYVIVRYTKMKTATNIYIFNLALADALAT STLPFQSVNYLMGTWPFGTILCKIVISIDYYNMFTSIFTLCTMSVDRYIAVCHPVKALDF RTPRNAKIINVCNWILSSAIGLPVMFMATTKYRQGSIDCTLTFSHPTWYWENLLKICVFI FAFIMPVLIITVCYGLMILRLKSVRMLSGSKEKDRNLRRITRMVLVVVAVFIVCWTPIHI YVIIKALVTIPETTFQTVSWHFCIALGYTNSCLNPVLYAFLDENFKRCFREFCIPTSSNI EQQNSTRIRQNTRDHPSTANTVDRTNHQLENLEAETAPLP |
||||
Drugs and Mode of Action | |||||
Drug(s) | Alfentanil | Drug Info | Approved | Anesthesia | [1], [2] |
Alvimopan | Drug Info | Approved | Gastrointestinal disease; Pain | [3], [4], [5] | |
Anileridine | Drug Info | Approved | Pain | [6], [7] | |
Anileridine Hydrochloride | Drug Info | Approved | Systemic pain | [8] | |
Buprenorphine | Drug Info | Approved | Pain | [9], [10] | |
Diphenoxylate | Drug Info | Approved | Diarrhea | [11], [12] | |
Eluxadoline | Drug Info | Approved | Diarrhea-predominant IBS | [13], [14] | |
Fentanyl | Drug Info | Approved | Analgesia | [8] | |
Hydrocodone | Drug Info | Approved | Pain | [15], [16] | |
Levomethadyl Acetate | Drug Info | Approved | Opiate dependence | [17], [18] | |
Levopropoxyphene Napsylate Anhydrous | Drug Info | Approved | Cough | [8] | |
Methadyl Acetate | Drug Info | Approved | Opiate dependence | [19] | |
Methylnaltrexone bromide | Drug Info | Approved | Opioid-induced constipation | [3] | |
Morphine | Drug Info | Approved | Chronic pain | [8] | |
Naloxegol | Drug Info | Approved | Opioid-induced constipation | [20], [21], [8] | |
Naloxone | Drug Info | Approved | Narcotic depression | [22], [23] | |
Propoxyphene Hydrochloride | Drug Info | Approved | Mild pain | [8] | |
Remifentanil | Drug Info | Approved | General anesthesia | [24], [25] | |
Tapentadol hydrochloride | Drug Info | Approved | Moderate-to-severe acute pain | [3] | |
ALKS5461 | Drug Info | Phase 3 | Major depressive disorder | [26] | |
GRT-6005 | Drug Info | Phase 3 | Diabetic neuropathy | [27] | |
Low dose fentanyl | Drug Info | Phase 3 | Pain | [28] | |
Morphine-6-glucuronide | Drug Info | Phase 3 | Pain | [29] | |
Nalbuphine hydrochloride ER | Drug Info | Phase 3 | Pain | [30] | |
NKTR-181 | Drug Info | Phase 3 | Pain | [31] | |
TRK-820 | Drug Info | Phase 3 | Discovery agent | [32] | |
BEMA buprenorphine transmucosal | Drug Info | Phase 2 | Migraine | [33] | |
Carfentanil | Drug Info | Phase 2 | Discovery agent | [34] | |
MAL formulation | Drug Info | Phase 2 | Opiate dependence | [35] | |
TD-1211 | Drug Info | Phase 2 | Opioid-induced constipation | [36] | |
TPM-1/Morphine | Drug Info | Phase 2 | Pain | [37] | |
AIKO-150 | Drug Info | Phase 1 | Opiate dependence | [38] | |
Buccal fentanyl | Drug Info | Phase 1 | Pain | [39] | |
Cyt-1010 | Drug Info | Phase 1 | Pain | [40] | |
GBR-12909 | Drug Info | Phase 1 | Discovery agent | [41] | |
GSK1521498 | Drug Info | Phase 1 | Obesity | [42] | |
Hydromorphone prodrug | Drug Info | Phase 1 | Pain | [43] | |
KP-201 hydrocodone prodrug | Drug Info | Phase 1 | Pain | [44] | |
MCP-201 | Drug Info | Phase 1 | Pain | [45] | |
NOCICEPTIN | Drug Info | Phase 1 | Headache | [46] | |
GNTI | Drug Info | Preclinical | Obesity | [47] | |
LY-25582 | Drug Info | Preclinical | Obesity | [47] | |
ADL-5945 | Drug Info | Discontinued in Phase 2 | Constipation | [48] | |
BCH-2687 | Drug Info | Discontinued in Phase 2 | Pain | [49] | |
DPI-3290 | Drug Info | Discontinued in Phase 2 | Pain | [50] | |
DYNORPHIN A | Drug Info | Discontinued in Phase 2 | Discovery agent | [51], [52] | |
Frakefamide | Drug Info | Discontinued in Phase 2 | Pain | [49] | |
MIRFENTANIL HYDROCHLORIDE | Drug Info | Discontinued in Phase 2 | Pain | [53] | |
Transdur-sufentanil | Drug Info | Discontinued in Phase 2 | Pain | [54] | |
TREFENTANIL HYDROCHLORIDE | Drug Info | Discontinued in Phase 2 | Pain | [55] | |
ADL-7445 | Drug Info | Discontinued in Phase 1 | Constipation | [56] | |
Fentanyl MDTS | Drug Info | Discontinued in Phase 1 | Pain | [57] | |
KN-203 | Drug Info | Discontinued in Phase 1 | Urinary incontinence | [58] | |
VP004 | Drug Info | Discontinued in Phase 1 | Substance dependence | [59] | |
443C81 | Drug Info | Terminated | Asthma | [60] | |
BCH-150 | Drug Info | Terminated | Gastrointestinal disease | [61] | |
BIPHALIN | Drug Info | Terminated | Discovery agent | [62] | |
DBO-11 | Drug Info | Terminated | Cancer pain | [63] | |
DBO-17 | Drug Info | Terminated | Cancer pain | [64] | |
LY-255582 | Drug Info | Terminated | Discovery agent | [65] | |
Sameridine | Drug Info | Terminated | Pain | [66] | |
SB-213698 | Drug Info | Terminated | Discovery agent | [67] | |
SNF-9007 | Drug Info | Terminated | Discovery agent | [68] | |
Inhibitor | (+/-)-nantenine | Drug Info | [69] | ||
(+/-)-TRANS-U-50488 METHANESULFONATE | Drug Info | [70] | |||
(-)-cyclorphan | Drug Info | [71] | |||
(-)-eseroline | Drug Info | [70] | |||
(H-Dmt-Tic-Glu-NH-(CH(2))(5)-CO-Dap(6DMN)-NH(2) | Drug Info | [72] | |||
1,10-bis-(Dmt-Tic-amino)decane | Drug Info | [73] | |||
1,4-bis-(Dmt-Tic-amino)butane | Drug Info | [73] | |||
1,6-bis-(Dmt-Tic-amino)hexane | Drug Info | [73] | |||
1,6-bis-(N,N-dimethyl-Dmt-Tic-NH)hexane | Drug Info | [73] | |||
1-(1,2-diphenylethyl)-4-phenylpiperidin-4-ol | Drug Info | [74] | |||
1-(2-ethoxy-1-phenylethyl)-4-phenylpiperidin-4-ol | Drug Info | [74] | |||
1-(dio-tolylmethyl)-4-phenylpiperidin-4-ol | Drug Info | [74] | |||
1-benzhydryl-4-(2-fluorophenyl)piperidin-4-ol | Drug Info | [75] | |||
1-benzhydryl-4-(2-methoxyphenyl)piperidin-4-ol | Drug Info | [75] | |||
1-benzhydryl-4-(3-fluorophenyl)piperidin-4-ol | Drug Info | [75] | |||
1-benzhydryl-4-(3-methoxyphenyl)piperidin-4-ol | Drug Info | [75] | |||
1-benzhydryl-4-(3-phenylpropyl)piperidin-4-ol | Drug Info | [75] | |||
1-benzhydryl-4-(4-bromophenyl)piperidin-4-ol | Drug Info | [75] | |||
1-benzhydryl-4-(4-chlorophenyl)piperidin-4-ol | Drug Info | [75] | |||
1-benzhydryl-4-(4-ethylphenyl)piperidin-4-ol | Drug Info | [75] | |||
1-benzhydryl-4-(4-fluorophenyl)piperidin-4-ol | Drug Info | [75] | |||
1-benzhydryl-4-(4-methoxyphenyl)piperidin-4-ol | Drug Info | [75] | |||
1-benzhydryl-4-(4-propylphenyl)piperidin-4-ol | Drug Info | [75] | |||
1-benzhydryl-4-(furan-2-yl)piperidin-4-ol | Drug Info | [75] | |||
1-benzhydryl-4-(pyridin-2-yl)piperidin-4-ol | Drug Info | [75] | |||
1-benzhydryl-4-(thiophen-2-yl)piperidin-4-ol | Drug Info | [75] | |||
1-benzhydryl-4-benzylpiperidin-4-ol | Drug Info | [75] | |||
1-benzhydryl-4-butylpiperidin-4-ol | Drug Info | [75] | |||
1-benzhydryl-4-cyclohexylpiperidin-4-ol | Drug Info | [75] | |||
1-benzhydryl-4-cyclopropylpiperidin-4-ol | Drug Info | [75] | |||
1-benzhydryl-4-ethoxy-4-phenylpiperidine | Drug Info | [74] | |||
1-benzhydryl-4-hexylpiperidin-4-ol | Drug Info | [75] | |||
1-benzhydryl-4-isopropylpiperidin-4-ol | Drug Info | [75] | |||
1-benzhydryl-4-m-tolylpiperidin-4-ol | Drug Info | [75] | |||
1-benzhydryl-4-methoxy-4-phenylpiperidine | Drug Info | [74] | |||
1-benzhydryl-4-o-tolylpiperidin-4-ol | Drug Info | [75] | |||
1-benzhydryl-4-p-tolylpiperidin-4-ol | Drug Info | [75] | |||
1-benzhydryl-4-phenyl-4-propoxypiperidine | Drug Info | [74] | |||
1-benzhydryl-4-phenylpiperidin-4-ol | Drug Info | [76] | |||
1-benzhydryl-4-tert-butylpiperidin-4-ol | Drug Info | [75] | |||
1-[3-(3-biphenyl)-(1,2,4-triazol-4-yl) ]-3-phenol | Drug Info | [77] | |||
1-[3-(4-biphenyl)-(1,2,4-triazol-4-yl) ]-3-phenol | Drug Info | [77] | |||
14-O-phenylpropylnaltrexone | Drug Info | [78] | |||
17-(Cyclobutylmethyl)-N-phenylmorphinan-3-amine | Drug Info | [79] | |||
17-(Cyclopropylmethyl)-N-phenylmorphinan-3-amine | Drug Info | [79] | |||
17-methyl-4'-methyldihydromorphinone | Drug Info | [80] | |||
17-Methylmorphinan-3-yl 4-Iodophenyl Carbamate | Drug Info | [79] | |||
2-(2-methylquinolin-4-ylamino)-N-phenylacetamide | Drug Info | [81] | |||
2-Benzylaminomethyl-3-hydroxymorphinan | Drug Info | [79] | |||
2-Hydroxymethyl-3-hydroxymorphinan | Drug Info | [79] | |||
3,6-bis(Dmt-Tic-NH-butyl)-2(1H)-pyrazinone | Drug Info | [73] | |||
3,6-bis(Dmt-Tic-NH-ethyl)-2(1H)-pyrazinone | Drug Info | [73] | |||
3,6-bis(Dmt-Tic-NH-methyl)-2(1H)-pyrazinone | Drug Info | [73] | |||
3,6-bis(Dmt-Tic-NH-propyl)-2(1H)-pyrazinone | Drug Info | [73] | |||
3-(1-benzylpiperidin-4-yl)-5-chloro-1H-indole | Drug Info | [82] | |||
3-(2-Methyl-2-aza-bicyclo[3.3.1]non-5-yl)-phenol | Drug Info | [83] | |||
3-desoxy-3-carboxamidonaltrexone | Drug Info | [84] | |||
4-(4-((phenethylamino)methyl)phenoxy)benzamide | Drug Info | [85] | |||
4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one | Drug Info | [86] | |||
4-(Spiro[chromene-2,4'-piperidine]-4-yl)benzamide | Drug Info | [87] | |||
4-(Spiro[chromene-2,4'-piperidine]-4-yl)phenol | Drug Info | [88] | |||
4-phenyl-1-(1-phenylbutyl)piperidin-4-ol | Drug Info | [74] | |||
4-phenyl-1-(1-phenylethyl)piperidin-4-ol | Drug Info | [74] | |||
4-phenyl-1-(1-phenylheptyl)piperidin-4-ol | Drug Info | [74] | |||
4-phenyl-1-(1-phenylhexyl)piperidin-4-ol | Drug Info | [74] | |||
4-phenyl-1-(1-phenylpentyl)piperidin-4-ol | Drug Info | [74] | |||
4-phenyl-1-(1-phenylpropyl)piperidin-4-ol | Drug Info | [74] | |||
4-phenyl-1-(phenyl(m-tolyl)methyl)piperidin-4-ol | Drug Info | [74] | |||
4-phenyl-1-(phenyl(o-tolyl)methyl)piperidin-4-ol | Drug Info | [74] | |||
4-phenyl-1-(phenyl(p-tolyl)methyl)piperidin-4-ol | Drug Info | [74] | |||
5-(4-((phenethylamino)methyl)phenoxy)picolinamide | Drug Info | [85] | |||
6-(2-benzylisoindolin-5-yloxy)nicotinamide | Drug Info | [89] | |||
6-(2-phenethylisoindolin-5-yloxy)nicotinamide | Drug Info | [89] | |||
6-(4-((benzylamino)methyl)phenoxy)nicotinamide | Drug Info | [85] | |||
6-(4-((phenethylamino)methyl)phenoxy)nicotinamide | Drug Info | [89] | |||
6-(4-(2-(benzylamino)ethyl)phenoxy)nicotinamide | Drug Info | [89] | |||
6-(4-(2-(benzylamino)ethyl)phenoxy)picolinamide | Drug Info | [85] | |||
6-(4-(3-(benzylamino)propyl)phenoxy)nicotinamide | Drug Info | [85] | |||
6-(Allyl-methyl-amino)-4,4-diphenyl-heptan-3-ol | Drug Info | [90] | |||
6-desoxonaltrexone | Drug Info | [84] | |||
6beta-naltrexol HCl | Drug Info | [91] | |||
8-azabicyclo[3.2.1]octan-3-yloxy-benzamide | Drug Info | [92] | |||
8-carboxamidocyclazocine | Drug Info | [93] | |||
Ac-D-pro-L-Phe-D-trp-L-Phe-NH2 | Drug Info | [94] | |||
Ac-L-Phe-D-trp-L-Phe-D-pro-NH2 | Drug Info | [94] | |||
Ac-RYYRIK-GGG-K-(NH2)-YAFGYPS-GG | Drug Info | [95] | |||
Ac-RYYRIK-GGG-K-(NH2)-YRFB-GGGGG | Drug Info | [95] | |||
Ac-RYYRIK-K-(NH2)-YAFGYPS | Drug Info | [95] | |||
Ac-RYYRIK-K-(NH2)-YRFB | Drug Info | [95] | |||
Ac-YGGFL-NH2 | Drug Info | [96] | |||
AKUAMMINE | Drug Info | [70] | |||
AMINOFENTANYL | Drug Info | [97] | |||
Antanal 1 | Drug Info | [98] | |||
Antanal 2 | Drug Info | [98] | |||
Benzyl derivative of M6G | Drug Info | [99] | |||
Beta-funaltrexamine | Drug Info | [100] | |||
BIPHALIN | Drug Info | [101] | |||
Bis-((-)-N-propargylmorphinan-3-yl) sebacoylate | Drug Info | [71] | |||
BREMAZOCINE | Drug Info | [102] | |||
BUTORPHAN | Drug Info | [103] | |||
C6S | Drug Info | [104] | |||
CARBOXYFENTANYL | Drug Info | [105] | |||
CCDC 710249, HCl salt | Drug Info | [84] | |||
Cis-H-Tyr-c[D-AllylGly-Gly-Phe-D-Allylgly]-OH | Drug Info | [106] | |||
Clocinnamox | Drug Info | [78] | |||
CODEINONE | Drug Info | [107] | |||
CYCLAZOCINE | Drug Info | [103] | |||
CYCLORPHAN | Drug Info | [103] | |||
CYPRODIME | Drug Info | [108] | |||
C[L-Ala-D-pro-L-Phe-D-trp] | Drug Info | [94] | |||
C[L-mTyr-D-pro-L-Phe-D-trp] | Drug Info | [94] | |||
C[L-Phe-D-pro-L-mTyr-D-trp] | Drug Info | [94] | |||
C[L-Phe-D-pro-L-Phe-D-trp] | Drug Info | [94] | |||
C[L-Phe-D-pro-L-Phe-L-trp] | Drug Info | [94] | |||
C[L-Phe-D-pro-L-Tyr(OMe)-D-trp] | Drug Info | [94] | |||
C[L-Phe-D-pro-L-Tyr-D-trp] | Drug Info | [94] | |||
C[L-Tyr(OMe)-D-pro-L-Phe-D-trp] | Drug Info | [94] | |||
C[L-Tyr-D-pro-L-Phe-D-trp] | Drug Info | [94] | |||
D-Phe-Cys-Tyr--Trp-Lys-Thr-Pen-Thr-NH2 | Drug Info | [109] | |||
D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2(CTAP) | Drug Info | [109] | |||
D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH2(CTP) | Drug Info | [109] | |||
D-PhGly-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH2 | Drug Info | [109] | |||
DAMGO | Drug Info | [110] | |||
DC6S | Drug Info | [104] | |||
Dcp-c[D-Cys-Gly-Phe(pNO2)-D-Cys]NH2 | Drug Info | [111] | |||
Delta-kappa opioid heterodimer | Drug Info | [112] | |||
DELTORPHIN | Drug Info | [113] | |||
DELTORPHIN-II | Drug Info | [114] | |||
Deprotected cogener of M6G | Drug Info | [99] | |||
DERMORPHIN | Drug Info | [95] | |||
Dhp-c[D-Cys-Gly-Phe(pNO2)-D-Cys]NH2 | Drug Info | [111] | |||
DIHYDROAKUAMMINE | Drug Info | [70] | |||
Dimepheptanol | Drug Info | [90] | |||
DM3A6S | Drug Info | [104] | |||
DM3B6S | Drug Info | [104] | |||
DM6S | Drug Info | [104] | |||
Dmt-Pro-3,5Dmp-Phe-NH2 | Drug Info | [115] | |||
Dmt-Pro-Dmp-Phe-NH2 | Drug Info | [115] | |||
Dmt-Pro-Dmt-Phe-NH2 | Drug Info | [115] | |||
Dmt-Pro-Emp-Phe-NH2 | Drug Info | [115] | |||
Dmt-Pro-Imp-Phe-NH2 | Drug Info | [115] | |||
Dmt-Pro-Mmp-Phe-NH2 | Drug Info | [115] | |||
Dmt-Pro-Phe-D-1-Nal-NH2 | Drug Info | [116] | |||
Dmt-Pro-Phe-D-2-Nal-NH2 | Drug Info | [116] | |||
Dmt-Pro-Phe-Phe-NH2 | Drug Info | [115] | |||
Dmt-Pro-Tmp-Phe-NH2 | Drug Info | [115] | |||
Dmt-Pro-Trp-D-2-Nal-NH2 | Drug Info | [116] | |||
Dmt-Sar-Phe-D-2-Nal-NH | Drug Info | [117] | |||
DPDPE | Drug Info | [110] | |||
DYNORPHIN A | Drug Info | [118] | |||
Dynorphin(1-8) | Drug Info | [119] | |||
ELAEOCARPENINE | Drug Info | [120] | |||
ENDOMORPHIN 2 | Drug Info | [121] | |||
ENDOMORPHIN-1 | Drug Info | [122] | |||
ETONITAZENE | Drug Info | [123] | |||
FALCARINDIOL | Drug Info | [124] | |||
FLUPERAMIDE | Drug Info | [125] | |||
GBR-12909 | Drug Info | [126] | |||
GUANIDINONALTRINDOLE | Drug Info | [127] | |||
H-2',6'-dimethyltyrosine-Tic-OH | Drug Info | [128] | |||
H-2',6'-dimethyltyrosine-Tic-Phe-Phe-OH | Drug Info | [128] | |||
H-Aba-ala-Gly-Phe-leu-OH | Drug Info | [129] | |||
H-Aba-ala-Gly-Phe-Met-OH | Drug Info | [129] | |||
H-Aba-Gly-Gly-Phe-Leu-OH | Drug Info | [129] | |||
H-Aba-ser-Gly-Phe-Leu-Thr-OH | Drug Info | [129] | |||
H-Apa-ala-Gly-Phe-leu-OH | Drug Info | [129] | |||
H-Cdp-ala-Gly-Phe-leu-OH | Drug Info | [129] | |||
H-Cdp-Gly-Gly-Phe-Leu-OH | Drug Info | [129] | |||
H-Cdp-ser-Gly-Phe-Leu-Thr-OH | Drug Info | [129] | |||
H-Cpa-Gly-Gly-Phe-Met-NH2 | Drug Info | [129] | |||
H-Cpa-Gly-Gly-Phe-Met-OH | Drug Info | [129] | |||
H-D-Phe-c[Cys-Tyr-DTrp-Orn-Thr-Pen]-Thr-NH2 | Drug Info | [98] | |||
H-D-Tca-c[Cys-Tyr-D-Trp-Arg-Thr-Pen]-Thr-NH2 | Drug Info | [130] | |||
H-D-Tic-c[Cys-Tyr-D-Trp-Arg-Thr-Pen]-Thr-NH2 | Drug Info | [130] | |||
H-D-Trp-c[Cys-Tyr-D-Trp-Arg-Thr-Pen]-Thr-NH2 | Drug Info | [130] | |||
H-Dmt-Aba-Gly-NH-CH2-Bid | Drug Info | [131] | |||
H-Dmt-Aba-Gly-NH-CH2-Ph | Drug Info | [131] | |||
H-Dmt-Aba-Gly-NH-Ph | Drug Info | [131] | |||
H-Dmt-D-Arg(NO2)-Phe-Lys(Z)-NH2 | Drug Info | [132] | |||
H-Dmt-D-Arg(NO2)-Phe-Lys(Z)-OH | Drug Info | [132] | |||
H-Dmt-Tic-(2R,3R)-beta-MeCha-Phe-NH2 | Drug Info | [133] | |||
H-Dmt-Tic-(2R,3R)-beta-MeCha-Phe-OH | Drug Info | [133] | |||
H-Dmt-Tic-(2R,3S)-beta-MeCha-Phe-NH2 | Drug Info | [133] | |||
H-Dmt-Tic-(2R,3S)-beta-MeCha-Phe-OH | Drug Info | [133] | |||
H-Dmt-Tic-(2S,3R)-beta-MeCha-Phe-NH2 | Drug Info | [133] | |||
H-Dmt-Tic-(2S,3R)-beta-MeCha-Phe-OH | Drug Info | [133] | |||
H-Dmt-Tic-(2S,3S)-beta-MeCha-Phe-NH2 | Drug Info | [133] | |||
H-Dmt-Tic-(2S,3S)-beta-MeCha-Phe-OH | Drug Info | [133] | |||
H-Dmt-Tic-Asp-N(Me)-Ph | Drug Info | [134] | |||
H-Dmt-Tic-Asp-NH-Bzl | Drug Info | [134] | |||
H-Dmt-Tic-Asp-NH-Ph | Drug Info | [134] | |||
H-Dmt-Tic-D-Asp-N(Me)-Ph | Drug Info | [134] | |||
H-Dmt-Tic-D-Asp-NH-Ph | Drug Info | [134] | |||
H-Dmt-Tic-Glu-Dap(6DMN)-NH(2) | Drug Info | [72] | |||
H-Dmt-Tic-Glu-NH-(CH2)5-NH2 | Drug Info | [135] | |||
H-Dmt-Tic-Glu-NH2 | Drug Info | [135] | |||
H-Dmt-Tic-Gly-N(Me)-Ph | Drug Info | [134] | |||
H-Dmt-Tic-Gly-NH-Bzl | Drug Info | [134] | |||
H-Dmt-Tic-Gly-NH-CH2-Bid | Drug Info | [131] | |||
H-Dmt-Tic-Gly-NH-Ph | Drug Info | [134] | |||
H-Dmt-Tic-Lys(Ac)-NH-CH2-Ph | Drug Info | [136] | |||
H-Dmt-Tic-Lys(Ac)-NH-Ph | Drug Info | [136] | |||
H-Dmt-Tic-Lys(Z)-NH-CH2-Ph | Drug Info | [136] | |||
H-Dmt-Tic-Lys(Z)-NH-Ph | Drug Info | [136] | |||
H-Dmt-Tic-Lys-NH-CH2-Ph | Drug Info | [136] | |||
H-Dmt-Tic-Lys-NH-Ph | Drug Info | [136] | |||
H-Dmt-Tic-NH-(CH2)6-NH-Dmt-H | Drug Info | [137] | |||
H-Dmt-Tic-NH-(CH2)6-NH-Phe-H | Drug Info | [137] | |||
H-Dmt-Tic-NH-(CH2)6-NH-Tic-H | Drug Info | [137] | |||
H-Dmt-Tic-NH-(D)-CH[(CH2)4-NH-Z]-Bid | Drug Info | [136] | |||
H-Dmt-Tic-NH-(R)CH(CH2-COOH)-Bid | Drug Info | [134] | |||
H-Dmt-Tic-NH-(R)CH(CH2-COOH)-Bid(N1-Me) | Drug Info | [134] | |||
H-Dmt-Tic-NH-(S)CH(CH2-COOH)-Bid(N1-Me) | Drug Info | [134] | |||
H-Dmt-Tic-NH-CH2-Boa | Drug Info | [138] | |||
H-Dmt-Tic-NH-CH2-Bta | Drug Info | [138] | |||
H-Dmt-Tic-NH-CH2-CH2-NH2 | Drug Info | [139] | |||
H-Dmt-Tic-NH-CH2-Imid | Drug Info | [138] | |||
H-Dmt-Tic-NH-CH2-ImidPh | Drug Info | [138] | |||
H-Dmt-Tic-NH-CH2-Indl | Drug Info | [138] | |||
H-Dmt-Tic-NH-CH2-Indn | Drug Info | [138] | |||
H-Dmt-Tic-NH-CH[(CH2)4-NH-Ac]-Bid | Drug Info | [136] | |||
H-Dmt-Tic-NH-CH[(CH2)4-NH-Z]-Bid | Drug Info | [136] | |||
H-Dmt-Tic-NH-CH[(CH2)4-NH2]-Bid | Drug Info | [136] | |||
H-Dmt-Tic-OH | Drug Info | [73] | |||
H-mCpa-ala-Gly-Phe-leu-OH | Drug Info | [129] | |||
H-mCpa-ser-Gly-Phe-Leu-Thr-OH | Drug Info | [129] | |||
H-Tyr-c[D-Allylgly-Gly-Phe-D-Allylgly]-OH | Drug Info | [106] | |||
H-Tyr-c[D-Allylgly-Gly-Phe-D-Allylgly]NH2 | Drug Info | [140] | |||
H-Tyr-c[D-Allylgly-Gly-Phe-L-Allylgly]NH2 | Drug Info | [140] | |||
H-Tyr-c[D-Cys-Gly-Phe-D-Cys]NH2 | Drug Info | [140] | |||
H-Tyr-c[D-Cys-Gly-Phe-L-Cys]NH2 | Drug Info | [140] | |||
H-Tyr-c[D-Orn-(D or L)Atc-Glu]-NH2 | Drug Info | [141] | |||
H-Tyr-c[D-Orn-Aic-Glu]-NH2 | Drug Info | [141] | |||
H-Tyr-D-Ala-(R or S)Atc-Asp-Val-Val-Gly-NH2 | Drug Info | [142] | |||
H-Tyr-D-Ala-Aic-Asp-Val-Val-Gly-NH2 | Drug Info | [142] | |||
H-Tyr-D-Ala-Gly Phe-Pro-Leu-Trp-O-3,5-Bzl(CF3)2 | Drug Info | [143] | |||
H-Tyr-D-Ala-Gly-Phe-D-Leu | Drug Info | [144] | |||
H-Tyr-D-Ala-Gly-Phe-NH-NH-(NMe)Phe-Asp-Nle-Trp-Ac | Drug Info | [145] | |||
H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Phe-D-Asp-D-Nle-Trp-H | Drug Info | [146] | |||
H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Trp-Nle-Asp-Phe-Bo | Drug Info | [146] | |||
H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Trp-Nle-Asp-Phe-H | Drug Info | [146] | |||
H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-D-Trp-Boc | Drug Info | [145] | |||
H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-D-Trp-H | Drug Info | [145] | |||
H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-Trp-Ac | Drug Info | [145] | |||
H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-Trp-Boc | Drug Info | [145] | |||
H-Tyr-D-Ala-Gly-Phe-NH-NH-Trp-D-Nle-D-Asp-D-Phe-H | Drug Info | [146] | |||
H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NH-3,5-Bzl(CF3)2 | Drug Info | [143] | |||
H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NH-Bzl | Drug Info | [143] | |||
H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NMe-3,5-Bzl(CF3)2 | Drug Info | [143] | |||
H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NMe-Bzl | Drug Info | [143] | |||
H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-O-Bzl | Drug Info | [143] | |||
H-Tyr-D-Ala-Tic-Asp-Val-Val-Gly-NH2 | Drug Info | [142] | |||
H-Tyr-Gly-Gly-Phe-Met-NH2 | Drug Info | [129] | |||
H-Tyr-Gly-Gly-Phe-Met-OH | Drug Info | [129] | |||
H-Tyr-Pro-Ala-Phe-NH2 | Drug Info | [96] | |||
H-Tyr-Pro-Dap(6DMN)-Phe-NH2 | Drug Info | [72] | |||
H-Tyr-Pro-Phe-Phe-NH-(CH2)5-(C=O)-Dap(6DMN)-NH2 | Drug Info | [72] | |||
H-Tyr-Pro-Phe-Phe-NH-CH2-CH2-NH Tic Dmt-H | Drug Info | [139] | |||
H-Tyr-Tic-Cha-Phe-OH | Drug Info | [133] | |||
H-Tyr-Tic-Phe-Phe-OH | Drug Info | [133] | |||
HERKINORIN | Drug Info | [147] | |||
HTyr-Gly-Gly-Phe-Leu-Arg-Arg-lle-Arg-Pro-LysNH2 | Drug Info | [148] | |||
Hydromorphone prodrug | Drug Info | [149] | |||
ICI-199441 | Drug Info | [150] | |||
KETOCYCLAZOCINE | Drug Info | [151] | |||
KNT-5 | Drug Info | [152] | |||
KNT-62 | Drug Info | [153] | |||
KNT-63 | Drug Info | [153] | |||
Leucine-enkephalin | Drug Info | [119] | |||
LOFENTANIL | Drug Info | [154] | |||
LY-255582 | Drug Info | [89] | |||
M3A6S | Drug Info | [104] | |||
M3B6S | Drug Info | [104] | |||
M3IBu6S | Drug Info | [104] | |||
M3P6S | Drug Info | [104] | |||
M3Pr6S | Drug Info | [104] | |||
M3S | Drug Info | [104] | |||
M6G thiosaccharide analogue | Drug Info | [99] | |||
M6S | Drug Info | [104] | |||
MC-CAM | Drug Info | [155] | |||
MCL-117 | Drug Info | [71] | |||
MCL-139 | Drug Info | [71] | |||
MCL-144 | Drug Info | [156] | |||
MCL-145 | Drug Info | [71] | |||
MCL-147 | Drug Info | [157] | |||
MCL-149 | Drug Info | [157] | |||
MCL-153 | Drug Info | [158] | |||
MCL-154 | Drug Info | [158] | |||
MCL-182 | Drug Info | [157] | |||
MCL-183 | Drug Info | [157] | |||
MCL-428 | Drug Info | [159] | |||
MCL-429 | Drug Info | [159] | |||
MCL-431 | Drug Info | [159] | |||
MCL-432 | Drug Info | [159] | |||
MCL-433 | Drug Info | [159] | |||
MCL-434 | Drug Info | [159] | |||
MCL-435 | Drug Info | [159] | |||
MCL-443 | Drug Info | [159] | |||
MCL-444 | Drug Info | [159] | |||
MCL-445 | Drug Info | [157] | |||
MCL-446 | Drug Info | [157] | |||
MCL-447 | Drug Info | [157] | |||
MCL-448 | Drug Info | [157] | |||
MCL-449 | Drug Info | [159] | |||
MCL-450 | Drug Info | [160] | |||
MCL-451 | Drug Info | [160] | |||
MCL-457 | Drug Info | [157] | |||
MCL-458 | Drug Info | [157] | |||
METAZOCINE | Drug Info | [161] | |||
MM3A6S | Drug Info | [104] | |||
MM3B6S | Drug Info | [104] | |||
MORPHICEPTIN | Drug Info | [121] | |||
MORPHINONE | Drug Info | [107] | |||
MR-1029 | Drug Info | [162] | |||
MR-1526 | Drug Info | [162] | |||
MR-2034 | Drug Info | [151] | |||
MR-2266 | Drug Info | [162] | |||
N-(17-Methylmorphinan-3-yl)-N'-phenylurea | Drug Info | [79] | |||
N-(4-Iodophenyl)-N'-(17-methylmorphinan-3-yl)urea | Drug Info | [79] | |||
N-alpha-amidino-Tyr(Me)-D-Pro-Gly-Trp-Phe-NH2 | Drug Info | [163] | |||
N-alpha-amidino-Tyr(Me)-Pro-Trp-p-Cl-Phe-NH2 | Drug Info | [163] | |||
N-alpha-amidino-Tyr(Me)-Pro-Trp-Phe-NH2 | Drug Info | [163] | |||
N-Benzyl-17-(cyclobutylmethyl)morphinan-3-amine | Drug Info | [79] | |||
N-Benzyl-17-(cyclopropylmethyl)morphinan-3-amine | Drug Info | [79] | |||
N-isobutylnoroxymorphone | Drug Info | [164] | |||
NalBzOH | Drug Info | [104] | |||
Naltrexone-6-alpha-ol | Drug Info | [151] | |||
Naltrexone-6-beta-ol | Drug Info | [151] | |||
NOCICEPTIN | Drug Info | [165] | |||
NORBINALTORPHIMINE | Drug Info | [166] | |||
O-DESMETHYL TRAMADOL | Drug Info | [151] | |||
Opioid Peptide [d-Ala(8)]Dynorphin derivative | Drug Info | [167] | |||
ORIPAVINE | Drug Info | [107] | |||
OXYMORPHINDOLE | Drug Info | [123] | |||
Oxymorphone semicarbazone hydrochloride | Drug Info | [119] | |||
PHENAZOCINE | Drug Info | [151] | |||
RTI-5989-31 | Drug Info | [168] | |||
SALVINORIN A | Drug Info | [147] | |||
SB-0304 | Drug Info | [169] | |||
SB-213698 | Drug Info | [170] | |||
SL-3111 | Drug Info | [171] | |||
SN-11 | Drug Info | [170] | |||
SN-23 | Drug Info | [170] | |||
SN-28 | Drug Info | [172] | |||
SNF-9007 | Drug Info | [173] | |||
SOMATOSTATIN | Drug Info | [109] | |||
SPIROINDANYLOXYMORPHONE | Drug Info | [174] | |||
THEBAINE | Drug Info | [107] | |||
TPM-1/Morphine | Drug Info | [175] | |||
Trans-H-Tyr-c[D-AllylGly-Gly-Phe-D-Allylgly]-OH | Drug Info | [106] | |||
TRK-820 | Drug Info | [153] | |||
Tyr-(NMe)Ala-L-Phe-D-Pro-NH2 | Drug Info | [176] | |||
Tyr-(R)-Aba-Gly-Phe-NH2 | Drug Info | [177] | |||
Tyr-(R)-spiro-Aba-Gly-Phe-NH2 | Drug Info | [177] | |||
Tyr-(S)-Aba-Gly-Phe-NH2 | Drug Info | [177] | |||
Tyr-(S)-spiro-Aba-Gly-Phe-NH2 | Drug Info | [177] | |||
Tyr-D-Ala-Gly-D-Trp-Nle-Asp-Phe-NH2 | Drug Info | [173] | |||
Tyr-D-Ala-Gly-D-Trp-NMeNle-Asp-Phe-NH2 | Drug Info | [173] | |||
Tyr-D-Ala-Gly-NMePhe | Drug Info | [100] | |||
Tyr-D-Ala-Gly-Phe-Met-NH2 | Drug Info | [101] | |||
Tyr-D-Ala-Gly-Phe-Met-Pro-Leu-Trp-NH-Bzl | Drug Info | [178] | |||
Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-NMeNle-D-Trp-Boc | Drug Info | [145] | |||
Tyr-D-Ala-Gly-Trp-Nle-Asp-Phe-NH2 | Drug Info | [173] | |||
Tyr-D-Ala-Gly-Trp-NMeNle-Asp-Phe-NH2 | Drug Info | [173] | |||
Tyr-D-Ala-Phe-Asp-Val-Val-Thr[Beta-D-Glc]-Gly-NH2 | Drug Info | [179] | |||
Tyr-D-Ala-Phe-Glu-Val-Val-Gly-NH2 | Drug Info | [180] | |||
Tyr-D-Ala-Phe-Gly-Tyr-Pro-Thr(Beta-D-Glc)-Gly-NH2 | Drug Info | [179] | |||
Tyr-D-Ala-Phe-Thr(-D-Glc)-Tyr-Pro-Ser-NH2 | Drug Info | [179] | |||
Tyr-D-Ala-Phe-Thr[-D-Glc(OAc)4]-Tyr-Pro-Ser-NH2 | Drug Info | [179] | |||
Tyr-D-Met-Phe-His-Leu-Met-Asp-NH2 | Drug Info | [180] | |||
Tyr-D-Nle-Gly-D-Trp-Nle-Asp-Phe-NH2 | Drug Info | [173] | |||
Tyr-D-Nle-Gly-D-Trp-NMeNle-Asp-Phe-NH2 | Drug Info | [173] | |||
Tyr-D-Nle-Gly-Trp-Nle-Asp-Phe-NH2 | Drug Info | [173] | |||
Tyr-D-Nle-Gly-Trp-NMeNle-Asp-Phe-NH2 | Drug Info | [173] | |||
Tyr-D-Phe-Gly-D-Trp-Nle-Asp-Phe-NH2 | Drug Info | [173] | |||
Tyr-D-Phe-Gly-D-Trp-NMeNle-Asp-Phe-NH2 | Drug Info | [173] | |||
Tyr-D-Phe-Gly-Trp-Nle-Asp-Phe-NH2 | Drug Info | [173] | |||
Tyr-D-Phe-Gly-Trp-NMeNle-Asp-Phe-NH2 | Drug Info | [173] | |||
Tyr-D-Pro-Gly-Trp-NMeNle-Asp-Phe-NH2 | Drug Info | [173] | |||
Tyr-Gly-Gly-Trp-NMeNle-Asp-Phe-NH2 | Drug Info | [173] | |||
Tyr-Pro-3,5Dmp-Phe-NH2 | Drug Info | [115] | |||
Tyr-Pro-D-(NMe)Phe-D-Pro-NH2 | Drug Info | [176] | |||
Tyr-Pro-D-Phe-D-Pro-NH2 | Drug Info | [176] | |||
Tyr-Pro-D-Phe-Pro-NH2 | Drug Info | [176] | |||
Tyr-Pro-D-Phg-Phe-NH2 | Drug Info | [181] | |||
Tyr-Pro-Dmp-Phe-NH2 | Drug Info | [115] | |||
Tyr-Pro-Dmt-Phe-NH2 | Drug Info | [115] | |||
Tyr-Pro-Emp-Phe-NH2 | Drug Info | [115] | |||
Tyr-Pro-Hfe-Phe-NH2 | Drug Info | [181] | |||
Tyr-Pro-Hfe-Pro-NH2 | Drug Info | [181] | |||
Tyr-Pro-Imp-Phe-NH2 | Drug Info | [115] | |||
Tyr-Pro-L-(NMe)Phe-D-Pro-NH2 | Drug Info | [176] | |||
Tyr-Pro-L-(NMe)Phe-Pro-NH2 | Drug Info | [176] | |||
Tyr-Pro-L-Phe-D-Pro-NH2 | Drug Info | [176] | |||
Tyr-Pro-L-Phe-Pro-NH2 | Drug Info | [176] | |||
Tyr-Pro-Mmp-Phe-NH | Drug Info | [115] | |||
Tyr-Pro-Phe-Ala-Bn | Drug Info | [182] | |||
Tyr-Pro-Phe-D-2-Nal-NH2 | Drug Info | [117] | |||
Tyr-Pro-Phe-D-Ala-Bn | Drug Info | [182] | |||
Tyr-Pro-Phe-D-Phg-NH2 | Drug Info | [181] | |||
Tyr-Pro-Phe-D-Val-Bn | Drug Info | [182] | |||
Tyr-Pro-Phe-Hfe-NH2 | Drug Info | [181] | |||
Tyr-Pro-Phe-Phe-N(CH3)2 | Drug Info | [183] | |||
Tyr-Pro-Phe-Phe-NHCH3 | Drug Info | [183] | |||
Tyr-Pro-Phe-Phe-NHNH2 | Drug Info | [183] | |||
Tyr-Pro-Phe-Phe-OC(CH3)3 | Drug Info | [183] | |||
Tyr-Pro-Phe-Phe-OCH2CH3 | Drug Info | [183] | |||
Tyr-Pro-Phe-Phe-OCH2OH | Drug Info | [183] | |||
Tyr-Pro-Phe-Phe-OCH3 | Drug Info | [183] | |||
Tyr-Pro-Phe-Phg-NH2 | Drug Info | [181] | |||
Tyr-Pro-Phg-Phe-NH2 | Drug Info | [181] | |||
Tyr-Pro-Phg-Pro-NH2 | Drug Info | [181] | |||
Tyr-Pro-Tmp-Phe-NH | Drug Info | [115] | |||
Tyr-Pro-Trp-D-Ala-Bn | Drug Info | [182] | |||
Tyr-Pro-Trp-D-Val-Bn | Drug Info | [182] | |||
Tyr-Pro-Trp-Gly-Bn | Drug Info | [182] | |||
Tyr-Sar-Phe-D-2-Nal-NH2 | Drug Info | [117] | |||
U-69593 | Drug Info | [104] | |||
UFP-502 | Drug Info | [114] | |||
UFP-512 | Drug Info | [114] | |||
YAWF-NH2 | Drug Info | [96] | |||
YGGWL-NH2 | Drug Info | [96] | |||
YGWFL-NH2 | Drug Info | [96] | |||
YPAA-NH2 | Drug Info | [96] | |||
YPWA-NH2 | Drug Info | [96] | |||
YRFB | Drug Info | [95] | |||
ZYKLOPHIN | Drug Info | [148] | |||
[D-Ala2]Met-enkephalinamide | Drug Info | [161] | |||
[Dcp1]Dyn A(1-11)-NH2 | Drug Info | [111] | |||
[Leu5]enkephalin | Drug Info | [184] | |||
[Tyr-Pro-Phe-NH-CH2-]2 | Drug Info | [185] | |||
[Tyr-Pro-Phe-NH-]2 | Drug Info | [185] | |||
[Tyr-Pro-Phe-Phe-NH-CH2-]2 | Drug Info | [185] | |||
[Tyr-Pro-Phe-Phe-NH-]2 | Drug Info | [185] | |||
Agonist | 3-Methylfentanyl | Drug Info | [186] | ||
3-Methylthiofentanyl | Drug Info | [187] | |||
Alfentanil | Drug Info | [188] | |||
ALKS5461 | Drug Info | [189] | |||
Anileridine | Drug Info | [190] | |||
BCH-2687 | Drug Info | [191] | |||
BEMA buprenorphine transmucosal | Drug Info | [192] | |||
Buprenorphine | Drug Info | [193], [194] | |||
Carfentanil | Drug Info | [195] | |||
Cyt-1010 | Drug Info | [196] | |||
DBO-11 | Drug Info | [197] | |||
DBO-17 | Drug Info | [197] | |||
Dihydromorphine | Drug Info | [198] | |||
Dimethylthiambutene | Drug Info | [199] | |||
Diphenoxylate | Drug Info | [200] | |||
DPI-3290 | Drug Info | [201] | |||
DSLET | Drug Info | [202] | |||
dynorphin B | Drug Info | [202] | |||
ethylketocyclazocine | Drug Info | [202] | |||
Ethylmorphine | Drug Info | [203] | |||
Etorphine | Drug Info | [204] | |||
Fentanyl MDTS | Drug Info | [205] | |||
Frakefamide | Drug Info | [206] | |||
GSK1521498 | Drug Info | [42], [207] | |||
KN-203 | Drug Info | [208] | |||
KP-201 hydrocodone prodrug | Drug Info | [209] | |||
Levomethadyl Acetate | Drug Info | [210] | |||
Low dose fentanyl | Drug Info | [205] | |||
MAL formulation | Drug Info | [211] | |||
MCP-201 | Drug Info | [212] | |||
Methadyl Acetate | Drug Info | [213] | |||
MIRFENTANIL HYDROCHLORIDE | Drug Info | [214], [8] | |||
Morphine-6-glucuronide | Drug Info | [197] | |||
NE-2 | Drug Info | [202] | |||
NKTR-181 | Drug Info | [215] | |||
normorphine | Drug Info | [202] | |||
NRP290 | Drug Info | [202] | |||
PL017 | Drug Info | [216] | |||
Remifentanil | Drug Info | [217] | |||
TQ-1017 | Drug Info | [8] | |||
Transdur-sufentanil | Drug Info | [218] | |||
TREFENTANIL HYDROCHLORIDE | Drug Info | [219], [8] | |||
Modulator | 443C81 | Drug Info | [220] | ||
AIKO-152 | Drug Info | [202] | |||
Anileridine Hydrochloride | Drug Info | [221] | |||
BCH-150 | Drug Info | [222] | |||
Buccal fentanyl | Drug Info | ||||
CC-408 | Drug Info | [202] | |||
Eluxadoline | Drug Info | ||||
Endomorphins | Drug Info | [202] | |||
Fentanyl | Drug Info | ||||
fentanyl (transmucosal film, pain), Auxilium Pharmaceuticals | Drug Info | [223] | |||
GRT-6005 | Drug Info | [27] | |||
Hydrocodone | Drug Info | ||||
KIN-3031 | Drug Info | [202] | |||
KRP-110 | Drug Info | [202] | |||
Levopropoxyphene Napsylate Anhydrous | Drug Info | [221] | |||
Methylnaltrexone bromide | Drug Info | [3] | |||
Morphine | Drug Info | ||||
Nalbuphine hydrochloride ER | Drug Info | ||||
Naloxegol | Drug Info | [20], [8] | |||
NCT-400 | Drug Info | [202] | |||
NRT-300 | Drug Info | [202] | |||
Propoxyphene Hydrochloride | Drug Info | ||||
PTI-601 | Drug Info | [202] | |||
Sameridine | Drug Info | [224] | |||
SEMORPHONE HYDROCHLORIDE | Drug Info | ||||
Tapentadol hydrochloride | Drug Info | [3] | |||
TD-1211 | Drug Info | [225] | |||
Antagonist | ADC-5510 | Drug Info | [202] | ||
ADL-5945 | Drug Info | [226] | |||
ADL-7445 | Drug Info | [226] | |||
AIKO-150 | Drug Info | [149] | |||
AIKO-151 | Drug Info | [202] | |||
Alvimopan | Drug Info | [227] | |||
Beta-endorphin | Drug Info | [228] | |||
CTAP | Drug Info | [216] | |||
CTOP | Drug Info | [229] | |||
Diprenorphine | Drug Info | [230] | |||
GNTI | Drug Info | [47] | |||
KIN-4044 | Drug Info | [202] | |||
KRP-100 | Drug Info | [202] | |||
LY-25582 | Drug Info | [47] | |||
naloxonazine | Drug Info | [229] | |||
Naloxone | Drug Info | [231], [232] | |||
naltriben | Drug Info | [202] | |||
PF-05 | Drug Info | [202] | |||
quadazocine | Drug Info | [202] | |||
[3H]diprenorphine | Drug Info | [229] | |||
[3H]naloxone | Drug Info | [229] | |||
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
TEP | EXP Info | ||||
Pathways | |||||
KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
Estrogen signaling pathway | |||||
Morphine addiction | |||||
NetPath Pathway | TCR Signaling Pathway | ||||
PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
Enkephalin release | |||||
Pathway Interaction Database | IL4-mediated signaling events | ||||
Reactome | Peptide ligand-binding receptors | ||||
G alpha (i) signalling events | |||||
WikiPathways | TCR Signaling Pathway | ||||
GPCRs, Class A Rhodopsin-like | |||||
Peptide GPCRs | |||||
Opioid Signalling | |||||
GPCR ligand binding | |||||
GPCR downstream signaling | |||||
References | |||||
REF 1 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 075221. | ||||
REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7108). | ||||
REF 3 | 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6. | ||||
REF 4 | Emerging drugs for postoperative ileus. Expert Opin Emerg Drugs. 2007 Nov;12(4):619-26. | ||||
REF 5 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7471). | ||||
REF 6 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7115). | ||||
REF 7 | Drug information of Anileridine, 2008. eduDrugs. | ||||
REF 8 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
REF 9 | Buprenorphine for opioid dependence. J Pain Palliat Care Pharmacother. 2009;23(2):153-5. | ||||
REF 10 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1670). | ||||
REF 11 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 040357. | ||||
REF 12 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7164). | ||||
REF 13 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7691). | ||||
REF 14 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031329) | ||||
REF 15 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 088017. | ||||
REF 16 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7081). | ||||
REF 17 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 020315. | ||||
REF 18 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7212). | ||||
REF 19 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 020315. | ||||
REF 20 | 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. | ||||
REF 21 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7539). | ||||
REF 22 | Opioid drug utilization and cost outcomes associated with the use of buprenorphine-naloxone in patients with a history of prescription opioid use. J Manag Care Pharm. 2008 Mar;14(2):186-94. | ||||
REF 23 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1668). | ||||
REF 24 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 020630. | ||||
REF 25 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7292). | ||||
REF 26 | ClinicalTrials.gov (NCT02158533) A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-4 Study. U.S. National Institutes of Health. | ||||
REF 27 | Cebranopadol: a first in-class example of a nociceptin/orphanin FQ receptor and opioid receptor agonist. Br J Anaesth. 2015 Mar;114(3):364-6. | ||||
REF 28 | A Phase III study to assess the clinical utility of low-dose fentanyl transdermal system in patients with chronic nonmalignant pain. Curr Med Res Opin. 2006 Aug;22(8):1493-501. | ||||
REF 29 | ClinicalTrials.gov (NCT01082471) An Efficacy and Safety Study to Compare Morphine 6-glucuronide (M6G) and Morphine in Patients Suffering With Post-Operative Pain for at Least 24 Hours. U.S. National Institutes of Health. | ||||
REF 30 | ClinicalTrials.gov (NCT00323154) Nalbuphine for the Treatment of Opioid Induced Pruritus in Children. U.S. National Institutes of Health. | ||||
REF 31 | ClinicalTrials.gov (NCT02362672) Efficacy and Safety Study of NKTR-181 in Opioid-Naive Subjects With Low Back Pain. U.S. National Institutes of Health. | ||||
REF 32 | ClinicalTrials.gov (NCT01513161) Efficacy and Safety Study of TRK-820 to Treat Conventional-treatment-resistant Pruritus in Patients Receiving Hemodialysis. U.S. National Institutes of Health. | ||||
REF 33 | ClinicalTrials.gov (NCT00941304) Study of BEMA Buprenorphine in the Treatment of Dental Pain. U.S. National Institutes of Health. | ||||
REF 34 | ClinicalTrials.gov (NCT01899170) Towards Individualized Deep Brain Stimulation Treatment of Chronic Neuropathic Pain. U.S. National Institutes of Health. | ||||
REF 35 | Clinical pipeline report, company report or official report of D&A Pharma. | ||||
REF 36 | ClinicalTrials.gov (NCT01401985) A Study of TD-1211 in Subjects With Opioid-Induced Constipation (OIC). U.S. National Institutes of Health. | ||||
REF 37 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023017) | ||||
REF 38 | ClinicalTrials.gov (NCT00829777) Safety Study of Intravenous 6??Naltrexol (AIKO-150) in Opioid-Dependent Subjects. U.S. National Institutes of Health. | ||||
REF 39 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017692) | ||||
REF 40 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035166) | ||||
REF 41 | ClinicalTrials.gov (NCT00218049) Interaction Between Vanoxerine (GBR 12909) and Cocaine in Cocaine Dependent Individuals. U.S. National Institutes of Health. | ||||
REF 42 | Clinical pipeline report, company report or official report of GlaxoSmithKline (2011). | ||||
REF 43 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034401) | ||||
REF 44 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800037883) | ||||
REF 45 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018011) | ||||
REF 46 | ClinicalTrials.gov (NCT01404091) A Study of Nociceptin/Orphanin FQ Peptide Receptor Occupancy in Healthy Subjects. U.S. National Institutes of Health. | ||||
REF 47 | Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. | ||||
REF 48 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030930) | ||||
REF 49 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009073) | ||||
REF 50 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010668) | ||||
REF 51 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1620). | ||||
REF 52 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005877) | ||||
REF 53 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003921) | ||||
REF 54 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015205) | ||||
REF 55 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003192) | ||||
REF 56 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031260) | ||||
REF 57 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020988) | ||||
REF 58 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026307) | ||||
REF 59 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025668) | ||||
REF 60 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000227) | ||||
REF 61 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003724) | ||||
REF 62 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008840) | ||||
REF 63 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009577) | ||||
REF 64 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009580) | ||||
REF 65 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005187) | ||||
REF 66 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005282) | ||||
REF 67 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006271) | ||||
REF 68 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006885) | ||||
REF 69 | Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31. Epub 2009 Nov 20.Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. | ||||
REF 70 | Akuammine and dihydroakuammine, two indolomonoterpene alkaloids displaying affinity for opioid receptors. J Nat Prod. 1992 Mar;55(3):380-4. | ||||
REF 71 | J Med Chem. 2006 Jan 12;49(1):256-62.Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opioid receptors. | ||||
REF 72 | J Med Chem. 2006 Jun 15;49(12):3653-8.6-N,N-dimethylamino-2,3-naphthalimide: a new environment-sensitive fluorescent probe in delta- and mu-selective opioid peptides. | ||||
REF 73 | J Med Chem. 2005 Dec 15;48(25):8035-44.Potent Dmt-Tic pharmacophoric delta- and mu-opioid receptor antagonists. | ||||
REF 74 | Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. | ||||
REF 75 | Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. | ||||
REF 76 | Bioorg Med Chem Lett. 2009 May 1;19(9):2519-23. Epub 2009 Mar 14.The discovery of tropane derivatives as nociceptin receptor ligands for the management of cough and anxiety. | ||||
REF 77 | J Med Chem. 2006 Jul 13;49(14):4044-7.Discovery of novel triazole-based opioid receptor antagonists. | ||||
REF 78 | J Med Chem. 2009 Mar 26;52(6):1553-7.14 beta-O-cinnamoylnaltrexone and related dihydrocodeinones are mu opioid receptor partial agonists with predominant antagonist activity. | ||||
REF 79 | J Med Chem. 2010 Jan 14;53(1):402-18.Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors. | ||||
REF 80 | J Med Chem. 2006 Aug 24;49(17):5333-8.Structural determinants of opioid activity in derivatives of 14-aminomorphinones: effect of substitution in the aromatic ring of cinnamoylaminomorphinones and codeinones. | ||||
REF 81 | Bioorg Med Chem. 2009 Aug 15;17(16):5782-90. Epub 2009 Jul 18.Synthesis and characterizations of novel quinoline derivatives having mixed ligand activities at the kappa and mu receptors: Potential therapeutic efficacy against morphine dependence. | ||||
REF 82 | Bioorg Med Chem Lett. 2006 Jul 1;16(13):3524-8. Epub 2006 Apr 24.3-(4-Piperidinyl)indoles and 3-(4-piperidinyl)pyrrolo-[2,3-b]pyridines as ligands for the ORL-1 receptor. | ||||
REF 83 | J Med Chem. 1992 May 1;35(9):1521-5.Phenylmorphans and analogues: opioid receptor subtype selectivity and effect of conformation on activity. | ||||
REF 84 | Bioorg Med Chem Lett. 2009 Apr 15;19(8):2289-94. Epub 2009 Feb 25.Syntheses of novel high affinity ligands for opioid receptors. | ||||
REF 85 | Bioorg Med Chem Lett. 2007 Oct 1;17(19):5349-52. Epub 2007 Aug 11.Structure-activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 1. | ||||
REF 86 | J Med Chem. 2010 Sep 9;53(17):6386-97.Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 receptor agonist with unprecedented selectivity and procognitive potential. | ||||
REF 87 | J Med Chem. 2009 Sep 24;52(18):5685-702.Spirocyclic delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-3-hydroxy-4-(spiro[chromene-2,4'-piperidine]-4-yl) benzamide (ADL5747). | ||||
REF 88 | J Med Chem. 2008 Oct 9;51(19):5893-6. Epub 2008 Sep 13.Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-piperidine]-4-yl)benzamide (ADL5859). | ||||
REF 89 | Bioorg Med Chem Lett. 2007 Dec 15;17(24):6841-6. Epub 2007 Oct 17.Structure activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 2. | ||||
REF 90 | J Med Chem. 1981 Jul;24(7):903-6.Synthesis of analogues of acetylmethadol and methadol as potential narcotic antagonists. | ||||
REF 91 | Bioorg Med Chem Lett. 2009 May 15;19(10):2811-4. Epub 2009 Mar 26.Design, synthesis, and characterization of 6beta-naltrexol analogs, and their selectivity for in vitro opioid receptor subtypes. | ||||
REF 92 | Bioorg Med Chem Lett. 2010 Sep 15;20(18):5405-10. Epub 2010 Aug 3.SAR development of a series of 8-azabicyclo[3.2.1]octan-3-yloxy-benzamides as kappa opioid receptor antagonists. Part 2. | ||||
REF 93 | Bioorg Med Chem. 2008 May 15;16(10):5653-64. Epub 2008 Mar 30.Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 6: Opioid receptor binding properties of cyclic variants of 8-carboxamidocyclazocine. | ||||
REF 94 | Bioorg Med Chem Lett. 2009 Jul 1;19(13):3647-50. Epub 2009 May 3.Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208. | ||||
REF 95 | Bioorg Med Chem Lett. 2006 Sep 15;16(18):4839-41. Epub 2006 Jun 30.Synthesis and receptor binding properties of chimeric peptides containing a mu-opioid receptor ligand and nociceptin/orphanin FQ receptor ligand Ac-RYYRIK-amide. | ||||
REF 96 | Bioorg Med Chem. 2008 Apr 15;16(8):4341-6. Epub 2008 Mar 4.Internalisation of the mu-opioid receptor by endomorphin-1 and leu-enkephalin is dependant on aromatic amino acid residues. | ||||
REF 97 | Bioorg Med Chem Lett. 2006 Sep 15;16(18):4946-50. Epub 2006 Jul 7.Synthesis and evaluation of 3-aminopropionyl substituted fentanyl analogues for opioid activity. | ||||
REF 98 | J Med Chem. 2008 Sep 25;51(18):5866-70.Novel opioid peptide derived antagonists containing (2S)-2-methyl-3-(2,6-dimethyl-4-carbamoylphenyl)propanoic acid [(2S)-Mdcp]. | ||||
REF 99 | Bioorg Med Chem Lett. 2005 Mar 15;15(6):1583-6.Synthesis and in vitro biological evaluation of a carbon glycoside analogue of morphine-6-glucuronide. | ||||
REF 100 | J Med Chem. 2009 Dec 10;52(23):7372-5.Discovery of dermorphin-based affinity labels with subnanomolar affinity for mu opioid receptors. | ||||
REF 101 | J Med Chem. 2010 Aug 12;53(15):5491-501.Biological and conformational evaluation of bifunctional compounds for opioid receptor agonists and neurokinin 1 receptor antagonists possessing two penicillamines. | ||||
REF 102 | J Med Chem. 1990 Aug;33(8):2286-96.Electrophilic alpha-methylene-gamma-lactone and isothiocyanate opioid ligands related to etorphine. | ||||
REF 103 | J Med Chem. 2000 Jan 13;43(1):114-22.Synthesis and opioid receptor affinity of morphinan and benzomorphan derivatives: mixed kappa agonists and mu agonists/antagonists as potential pharmacotherapeutics for cocaine dependence. | ||||
REF 104 | Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5. Epub 2006 Jun 13.Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. | ||||
REF 105 | J Med Chem. 2007 Nov 1;50(22):5528-32. Epub 2007 Oct 10.Development of novel enkephalin analogues that have enhanced opioid activities at both mu and delta opioid receptors. | ||||
REF 106 | J Med Chem. 2007 Jun 28;50(13):3138-42. Epub 2007 Jun 1.Synthesis of stable and potent delta/mu opioid peptides: analogues of H-Tyr-c[D-Cys-Gly-Phe-D-Cys]-OH by ring-closing metathesis. | ||||
REF 107 | J Biol Chem. 2007 Sep 14;282(37):27126-32. Epub 2007 Jul 6.Live cell monitoring of mu-opioid receptor-mediated G-protein activation reveals strong biological activity of close morphine biosynthetic precursors. | ||||
REF 108 | J Med Chem. 2004 Jun 3;47(12):3242-7.Synthesis and biological evaluation of 14-alkoxymorphinans. 21. Novel 4-alkoxy and 14-phenylpropoxy derivatives of the mu opioid receptor antagonist cyprodime. | ||||
REF 109 | J Med Chem. 1986 Nov;29(11):2370-5.Design and synthesis of conformationally constrained somatostatin analogues with high potency and specificity for mu opioid receptors. | ||||
REF 110 | Evaluation of N-substitution in 6,7-benzomorphan compounds. Bioorg Med Chem. 2010 Jul 15;18(14):4975-82. doi: 10.1016/j.bmc.2010.06.005. Epub 2010 Jun 9. | ||||
REF 111 | J Med Chem. 2006 Aug 24;49(17):5382-5.Replacement of the N-terminal tyrosine residue in opioid peptides with 3-(2,6-dimethyl-4-carbamoylphenyl)propanoic acid (Dcp) results in novel opioid antagonists. | ||||
REF 112 | J Med Chem. 2004 Jun 3;47(12):2969-72.A bivalent ligand (KDN-21) reveals spinal delta and kappa opioid receptors are organized as heterodimers that give rise to delta(1) and kappa(2) phenotypes. Selective targeting of delta-kappa heterodimers. | ||||
REF 113 | J Med Chem. 1991 May;34(5):1656-61.Synthesis and structure-activity relationships of deltorphin analogues. | ||||
REF 114 | Bioorg Med Chem. 2010 Aug 15;18(16):6024-30. Epub 2010 Jun 25.Role of 2',6'-dimethyl-l-tyrosine (Dmt) in some opioid lead compounds. | ||||
REF 115 | J Med Chem. 2007 Jun 14;50(12):2753-66. Epub 2007 May 12.Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mixed mu-agonist/delta-antagonist and dual mu-agonist/delta-agonist opioid ligands. | ||||
REF 116 | J Med Chem. 2007 Feb 8;50(3):512-20.Synthesis and characterization of potent and selective mu-opioid receptor antagonists, [Dmt(1), D-2-Nal(4)]endomorphin-1 (Antanal-1) and [Dmt(1), D-2-Nal(4)]endomorphin-2 (Antanal-2). | ||||
REF 117 | Bioorg Med Chem Lett. 2008 Feb 15;18(4):1350-3. Epub 2008 Jan 8.Novel highly potent mu-opioid receptor antagonist based on endomorphin-2 structure. | ||||
REF 118 | Bioorg Med Chem Lett. 2008 Jun 15;18(12):3667-71. Epub 2007 Dec 4.Use of receptor chimeras to identify small molecules with high affinity for the dynorphin A binding domain of the kappa opioid receptor. | ||||
REF 119 | J Med Chem. 1986 Jul;29(7):1222-5.Peptides as receptor selectivity modulators of opiate pharmacophores. | ||||
REF 120 | Bioorg Med Chem Lett. 2010 Mar 1;20(5):1601-3. Epub 2010 Jan 22.Synthesis and evaluation of opioid receptor-binding affinity of elaeocarpenine and its analogs. | ||||
REF 121 | Eur J Med Chem. 2010 Oct;45(10):4594-600. Epub 2010 Jul 21.Synthesis and activity of endomorphin-2 and morphiceptin analogues with proline surrogates in position 2. | ||||
REF 122 | Bioorg Med Chem Lett. 2009 Aug 1;19(15):4115-8. Epub 2009 Jun 6.Synthesis and evaluation of new endomorphin analogues modified at the Pro(2) residue. | ||||
REF 123 | Eur J Med Chem. 2008 Nov;43(11):2307-15. Epub 2008 Feb 29.Ligand binding to nucleic acids and proteins: Does selectivity increase with strength?. | ||||
REF 124 | Bioorg Med Chem. 2008 Mar 15;16(6):3218-23. Epub 2007 Dec 31.Novel coumarin glycoside and phenethyl vanillate from Notopterygium forbesii and their binding affinities for opioid and dopamine receptors. | ||||
REF 125 | Bioorg Med Chem Lett. 2004 Nov 1;14(21):5275-9.Design and synthesis of 4-phenyl piperidine compounds targeting the mu receptor. | ||||
REF 126 | J Med Chem. 2001 Oct 11;44(21):3391-401.From hit to lead. Analyzing structure-profile relationships. | ||||
REF 127 | J Med Chem. 2003 Jul 3;46(14):3127-37.Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist. | ||||
REF 128 | J Med Chem. 2009 Nov 12;52(21):6941-5.Agonist vs antagonist behavior of delta opioid peptides containing novel phenylalanine analogues in place of Tyr(1). | ||||
REF 129 | Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60. Epub 2007 Feb 2.Further studies of tyrosine surrogates in opioid receptor peptide ligands. | ||||
REF 130 | J Med Chem. 2000 Feb 24;43(4):569-80.Opiate aromatic pharmacophore structure-activity relationships in CTAP analogues determined by topographical bias, two-dimensional NMR, and biological activity assays. | ||||
REF 131 | J Med Chem. 2006 Jun 29;49(13):3990-3.New 2',6'-dimethyl-L-tyrosine (Dmt) opioid peptidomimetics based on the Aba-Gly scaffold. Development of unique mu-opioid receptor ligands. | ||||
REF 132 | J Med Chem. 2005 Aug 25;48(17):5608-11.From the potent and selective mu opioid receptor agonist H-Dmt-d-Arg-Phe-Lys-NH(2) to the potent delta antagonist H-Dmt-Tic-Phe-Lys(Z)-OH. | ||||
REF 133 | J Med Chem. 2007 Jan 25;50(2):328-33.Beta-methyl substitution of cyclohexylalanine in Dmt-Tic-Cha-Phe peptides results in highly potent delta opioid antagonists. | ||||
REF 134 | J Med Chem. 2008 Aug 28;51(16):5109-17. Epub 2008 Aug 5.Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic. | ||||
REF 135 | J Med Chem. 2004 Dec 16;47(26):6541-6.Highly selective fluorescent analogue of the potent delta-opioid receptor antagonist Dmt-Tic. | ||||
REF 136 | J Med Chem. 2006 Sep 7;49(18):5610-7.Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore. | ||||
REF 137 | Bioorg Med Chem Lett. 2005 Dec 15;15(24):5517-20. Epub 2005 Sep 23.New series of potent delta-opioid antagonists containing the H-Dmt-Tic-NH-hexyl-NH-R motif. | ||||
REF 138 | Bioorg Med Chem. 2008 Mar 15;16(6):3032-8. Epub 2007 Dec 23.Role of benzimidazole (Bid) in the delta-opioid agonist pseudopeptide H-Dmt-Tic-NH-CH(2)-Bid (UFP-502). | ||||
REF 139 | Bioorg Med Chem. 2007 Nov 15;15(22):6876-81. Epub 2007 Aug 29.A new opioid designed multiple ligand derived from the micro opioid agonist endomorphin-2 and the delta opioid antagonist pharmacophore Dmt-Tic. | ||||
REF 140 | J Med Chem. 2007 Mar 22;50(6):1414-7. Epub 2007 Feb 22.Dicarba analogues of the cyclic enkephalin peptides H-Tyr-c[D-Cys-Gly-Phe-D(or L)-Cys]NH(2) retain high opioid activity. | ||||
REF 141 | J Med Chem. 1991 Oct;34(10):3125-32.Conformational restriction of the phenylalanine residue in a cyclic opioid peptide analogue: effects on receptor selectivity and stereospecificity. | ||||
REF 142 | J Med Chem. 1993 Nov 26;36(24):3748-56.Phe3-substituted analogues of deltorphin C. Spatial conformation and topography of the aromatic ring in peptide recognition by delta opioid receptors. | ||||
REF 143 | J Med Chem. 2008 Mar 13;51(5):1369-76. Epub 2008 Feb 12.A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are delta/mu opioid receptor agonists and neurokinin 1 receptor antagonists. | ||||
REF 144 | J Med Chem. 2007 Jun 14;50(12):2779-86. Epub 2007 May 22.Design, synthesis, and biological evaluation of novel bifunctional C-terminal-modified peptides for delta/mu opioid receptor agonists and neurokinin-1 receptor antagonists. | ||||
REF 145 | J Med Chem. 2006 Mar 9;49(5):1773-80.Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists. | ||||
REF 146 | J Med Chem. 2007 Jan 11;50(1):165-8.Partial retro-inverso, retro, and inverso modifications of hydrazide linked bifunctional peptides for opioid and cholecystokinin (CCK) receptors. | ||||
REF 147 | J Med Chem. 2008 Apr 24;51(8):2421-31. Epub 2008 Apr 2.Herkinorin analogues with differential beta-arrestin-2 interactions. | ||||
REF 148 | J Med Chem. 2009 Nov 12;52(21):6814-21.The effects of C-terminal modifications on the opioid activity of [N-benzylTyr(1)]dynorphin A-(1-11) analogues. | ||||
REF 149 | Clinical pipeline report, company report or official report of signaturerx. | ||||
REF 150 | J Med Chem. 1994 Sep 2;37(18):2856-64.Isothiocyanate-substituted kappa-selective opioid receptor ligands derived from N-methyl-N-[(1S)-1-phenyl-2-(1-pyrrolidinyl)ethyl] phenylacetamide. | ||||
REF 151 | Bioorg Med Chem Lett. 2009 Jan 1;19(1):203-8. Epub 2008 Nov 7.Syntheses and opioid receptor binding properties of carboxamido-substituted opioids. | ||||
REF 152 | Bioorg Med Chem Lett. 2010 Feb 1;20(3):1055-8. Epub 2009 Dec 26.Investigation of Beckett-Casy model 1: synthesis of novel 16,17-seco-naltrexone derivatives and their pharmacology. | ||||
REF 153 | Bioorg Med Chem Lett. 2010 Jan 1;20(1):121-4. Epub 2009 Nov 13.Drug design and synthesis of a novel kappa opioid receptor agonist with an oxabicyclo[2.2.2]octane skeleton and its pharmacology. | ||||
REF 154 | J Med Chem. 1982 Aug;25(8):913-9.Potential affinity labels for the opiate receptor based on fentanyl and related compounds. | ||||
REF 155 | J Med Chem. 2009 Nov 12;52(21):6926-30.14beta-Arylpropiolylamino-17-cyclopropylmethyl-7,8-dihydronormorphinones and related opioids. Further examples of pseudoirreversible mu opioid receptor antagonists. | ||||
REF 156 | J Med Chem. 2009 Dec 10;52(23):7389-96.Univalent and bivalent ligands of butorphan: characteristics of the linking chain determine the affinity and potency of such opioid ligands. | ||||
REF 157 | Bioorg Med Chem. 2007 Jun 15;15(12):4106-12. Epub 2007 Mar 30.In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. | ||||
REF 158 | Bioorg Med Chem Lett. 2010 Mar 1;20(5):1507-9. Epub 2010 Jan 25.Effect of linker substitution on the binding of butorphan univalent and bivalent ligands to opioid receptors. | ||||
REF 159 | Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11. Epub 2007 Jan 17.High-affinity carbamate analogues of morphinan at opioid receptors. | ||||
REF 160 | J Med Chem. 2006 Sep 7;49(18):5640-3.New opioid designed multiple ligand from Dmt-Tic and morphinan pharmacophores. | ||||
REF 161 | J Med Chem. 1982 Dec;25(12):1423-7.Synthesis and biological evaluation of a metazocine-containing enkephalinamide. Evidence for nonidentical roles of the tyramine moiety in opiates and opioid peptides. | ||||
REF 162 | J Med Chem. 1991 Aug;34(8):2438-44.Electrophilic gamma-lactone kappa-opioid receptor probes. Analogues of 2'-hydroxy-2-tetrahydrofurfuryl-5,9-dimethyl-6,7-benzomorphan diastereomers. | ||||
REF 163 | Bioorg Med Chem. 2007 Feb 15;15(4):1694-702. Epub 2006 Dec 12.Endomorphin-1 analogs with enhanced metabolic stability and systemic analgesic activity: design, synthesis, and pharmacological characterization. | ||||
REF 164 | Bioorg Med Chem Lett. 2008 Sep 15;18(18):4978-81. Epub 2008 Aug 12.Synthesis of N-isobutylnoroxymorphone from naltrexone by a selective cyclopropane ring opening reaction. | ||||
REF 165 | J Med Chem. 2008 Feb 28;51(4):1058-62. Epub 2008 Jan 31.Synthesis and pharmacological evaluation of 1,2-dihydrospiro[isoquinoline-4(3H),4'-piperidin]-3-ones as nociceptin receptor agonists. | ||||
REF 166 | Bioorg Med Chem Lett. 2010 Sep 1;20(17):5035-8. Epub 2010 Jul 13.Synthesis of pyrrolomorphinan derivatives as kappa opioid agonists. | ||||
REF 167 | J Med Chem. 2003 Sep 11;46(19):4002-8.Effects of the substitution of Phe4 in the opioid peptide [D-Ala8]dynorphin A-(1-11)NH2. | ||||
REF 168 | J Med Chem. 2007 Aug 9;50(16):3765-76. Epub 2007 Jul 11.Probes for narcotic receptor mediated phenomena. 34. Synthesis and structure-activity relationships of a potent mu-agonist delta-antagonist and an exceedingly potent antinociceptive in the enantiomeric C9-substituted 5-(3-hydroxyphenyl)-N-phenylethylmorphan series. | ||||
REF 169 | J Med Chem. 2008 Apr 24;51(8):2571-4. Epub 2008 Mar 28.Blood-brain barrier penetration by two dermorphin tetrapeptide analogues: role of lipophilicity vs structural flexibility. | ||||
REF 170 | Bioorg Med Chem Lett. 2009 May 15;19(10):2792-5. Epub 2009 Mar 26.Design and synthesis of novel delta opioid receptor agonists and their pharmacologies. | ||||
REF 171 | J Med Chem. 1999 Dec 30;42(26):5359-68.Exploring the structure-activity relationships of [1-(4-tert-butyl-3'-hydroxy)benzhydryl-4-benzylpiperazine] (SL-3111), a high-affinity and selective delta-opioid receptor nonpeptide agonist ligand. | ||||
REF 172 | Bioorg Med Chem Lett. 2010 Nov 1;20(21):6302-5. Epub 2010 Aug 21.Design and synthesis of KNT-127, a |A-opioid receptor agonist effective by systemic administration. | ||||
REF 173 | J Med Chem. 2006 May 18;49(10):2868-75.Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. | ||||
REF 174 | Bioorg Med Chem. 2009 Aug 15;17(16):5983-8. Epub 2009 Jul 3.Aerobic oxidation of indolomorphinan without the 4,5-epoxy bridge and subsequent rearrangement of the oxidation product to spiroindolinonyl-C-normorphinan derivative. | ||||
REF 175 | Molecular Mechanisms of Opioid Receptor-Dependent Signaling and Behavior. Anesthesiology. 2011 December; 115(6): 1363-1381. | ||||
REF 176 | J Med Chem. 1993 Mar 19;36(6):708-19.A topochemical approach to explain morphiceptin bioactivity. | ||||
REF 177 | J Med Chem. 2008 Jan 10;51(1):173-7. Epub 2007 Dec 7.Endomorphin-2 with a beta-turn backbone constraint retains the potent micro-opioid receptor agonist properties. | ||||
REF 178 | J Med Chem. 2008 Oct 23;51(20):6334-47. Epub 2008 Sep 27.The importance of micelle-bound states for the bioactivities of bifunctional peptide derivatives for delta/mu opioid receptor agonists and neurokinin 1 receptor antagonists. | ||||
REF 179 | J Med Chem. 1997 Aug 29;40(18):2948-52.Synthesis and pharmacological activity of deltorphin and dermorphin-related glycopeptides. | ||||
REF 180 | J Med Chem. 1994 Jan 7;37(1):141-5.Design of cyclic deltorphins and dermenkephalins with a disulfide bridge leads to analogues with high selectivity for delta-opioid receptors. | ||||
REF 181 | Bioorg Med Chem Lett. 2006 Jul 15;16(14):3688-92. Epub 2006 May 8.Opioid receptor binding and antinociceptive activity of the analogues of endomorphin-2 and morphiceptin with phenylalanine mimics inthe position 3 or 4. | ||||
REF 182 | Bioorg Med Chem Lett. 2009 Sep 15;19(18):5387-91. Epub 2009 Jul 30.Molecular modeling studies to predict the possible binding modes of endomorphin analogs in mu opioid receptor. | ||||
REF 183 | Bioorg Med Chem. 2008 Jun 15;16(12):6415-22. Epub 2008 May 3.Structure-activity study of endomorphin-2 analogs with C-terminal modifications by NMR spectroscopy and molecular modeling. | ||||
REF 184 | J Med Chem. 2010 Apr 8;53(7):2875-81."Carba"-analogues of fentanyl are opioid receptor agonists. | ||||
REF 185 | Bioorg Med Chem Lett. 2005 Apr 1;15(7):1847-50.Structure-activity relationship of the novel bivalent and C-terminal modified analogues of endomorphin-2. | ||||
REF 186 | Subramanian G, Paterlini MG, Portoghese PS, Ferguson DM: Molecular docking reveals a novel binding site model for fentanyl at the mu-opioid receptor. J Med Chem. 2000 Feb 10;43(3):381-91. | ||||
REF 187 | You HJ, Colpaert FC, Arendt-Nielsen L: The novel analgesic and high-efficacy 5-HT1A receptor agonist F 13640 inhibits nociceptive responses, wind-up, and after-discharges in spinal neurons and withdrawal reflexes. Exp Neurol. 2005 Jan;191(1):174-83. | ||||
REF 188 | Concentration-effect relationship of intravenous alfentanil and ketamine on peripheral neurosensory thresholds, allodynia and hyperalgesia of neuropathic pain. Pain. 2001 Mar;91(1-2):177-87. | ||||
REF 189 | Abstracts of Poster Presentations: CNS Summit 2013: November 14-17, 2013 Boca Raton, Florida. Innov Clin Neurosci. 2013 Nov-Dec; 10(11-12 Suppl B): 1-18. | ||||
REF 190 | Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. | ||||
REF 191 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009073) | ||||
REF 192 | Effects of buprenorphine/naloxone in opioid-dependent humans. Psychopharmacology (Berl). 2001 Mar;154(3):230-42. | ||||
REF 193 | Partial versus full agonists for opioid-mediated analgesia--focus on fentanyl and buprenorphine. Acta Anaesthesiol Belg. 2002;53(3):193-201. | ||||
REF 194 | Buprenorphine is a weak partial agonist that inhibits opioid receptor desensitization. J Neurosci. 2009 Jun 3;29(22):7341-8. | ||||
REF 195 | Wax PM, Becker CE, Curry SC: Unexpected “gas” casualties in Moscow: a medical toxicology perspective. Ann Emerg Med. 2003 May;41(5):700-5. | ||||
REF 196 | Endomorphin-2: A Biased Agonist at the ?-Opioid Receptor. Mol Pharmacol. 2012 August; 82(2): 178-188. | ||||
REF 197 | Emerging analgesics in cancer pain management. Expert Opin Emerg Drugs. 2005 Feb;10(1):151-71. | ||||
REF 198 | Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5. Epub 2006 Jun 13. | ||||
REF 199 | How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. | ||||
REF 200 | Loperamide: a pharmacological review. Rev Gastroenterol Disord. 2007;7 Suppl 3:S11-8. | ||||
REF 201 | DPI-3290 [(+)-3-((alpha-R)-alpha-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N-(3-fluorophenyl)-N-methylbenzamide]. II. A mixed opioid agonist with potent antinociceptive activity and limited effects on respiratory function. J Pharmacol Exp Ther. 2003 Dec;307(3):1227-33. Epub 2003 Oct 8. | ||||
REF 202 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319). | ||||
REF 203 | Biotransformation and pharmacokinetics of ethylmorphine after a single oral dose. Br J Clin Pharmacol. 1995 Jun;39(6):611-20. | ||||
REF 204 | Internalization of mu-opioid receptors produced by etorphine in the rat locus coeruleus. Neuroscience. 2001;108(3):467-77. | ||||
REF 205 | Transdermal fentanyl versus sustained release oral morphine in strong-opioid na?ve patients with chronic low back pain. Spine (Phila Pa 1976). 2005 Nov 15;30(22):2484-90. | ||||
REF 206 | A novel molecule (frakefamide) with peripheral opioid properties: the effects on resting ventilation compared with morphine and placebo. Anesth Analg. 2005 Mar;100(3):713-7, table of contents. | ||||
REF 207 | Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). | ||||
REF 208 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026307) | ||||
REF 209 | Clinical pipeline report, company report or official report of kempharm. | ||||
REF 210 | Methadone-related opioid agonist pharmacotherapy for heroin addiction. History, recent molecular and neurochemical research and future in mainstream medicine. Ann N Y Acad Sci. 2000;909:186-216. | ||||
REF 211 | Clinical pipeline report, company report or official report of D&A Pharma. | ||||
REF 212 | US patent application no. 6,924,288, Enantiomerically pure opioid diarylmethylpiperzine and methods of using same. | ||||
REF 213 | Acetylmethadol metabolites influence opiate receptors and adenylate cyclase in amygdala. Eur J Pharmacol. 1981 Jul 10;72(4):343-9. | ||||
REF 214 | Mirfentanil: pharmacological profile of a novel fentanyl derivative with opioid and nonopioid effects. J Pharmacol Exp Ther. 1991 Aug;258(2):502-10. | ||||
REF 215 | A Review of Abuse-Deterrent Opioids For Chronic Nonmalignant Pain. P T. 2012 July; 37(7): 412-418. | ||||
REF 216 | Potent morphiceptin analogs: structure activity relationships and morphine-like activities. J Pharmacol Exp Ther. 1983 Nov;227(2):403-8. | ||||
REF 217 | The pro-nociceptive effects of remifentanil or surgical injury in mice are associated with a decrease in delta-opioid receptor mRNA levels: Prevention of the nociceptive response by on-site delivery of enkephalins. Pain. 2009 Jan;141(1-2):88-96. Epub 2008 Dec 5. | ||||
REF 218 | [3H]Sufentanil, a superior ligand for mu-opiate receptors: binding properties and regional distribution in rat brain and spinal cord. Eur J Pharmacol. 1983 Feb 18;87(2-3):209-25. | ||||
REF 219 | Pharmacokinetic-pharmacodynamic modeling in drug development: application to the investigational opioid trefentanil. Clin Pharmacol Ther. 1994 Sep;56(3):261-71. | ||||
REF 220 | Inhibition of cholinergic neurotransmission in human airways by opioids. J Appl Physiol (1985). 1992 Mar;72(3):1096-100. | ||||
REF 221 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | ||||
REF 222 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003724) | ||||
REF 223 | The ChEMBL database in 2017. | ||||
REF 224 | The effects on resting ventilation of intravenous infusions of morphine or sameridine, a novel molecule with both local anesthetic and opioid properties. Anesth Analg. 1999 Jan;88(1):160-5. | ||||
REF 225 | The in vitro pharmacological profile of TD-1211, a neutral opioid receptor antagonist. Naunyn Schmiedebergs Arch Pharmacol. 2013 Jun;386(6):479-91. | ||||
REF 226 | Novel opioid antagonists for opioid-induced bowel dysfunction. Expert Opin Investig Drugs. 2011 Aug;20(8):1047-56. | ||||
REF 227 | Alvimopan for postoperative ileus. Am J Health Syst Pharm. 2009 Jul 15;66(14):1267-77. | ||||
REF 228 | Beta-endorphin is a potent inhibitor of thymidine incorporation into DNA via mu- and kappa-opioid receptors in fetal rat brain cell aggregates in culture. J Neurochem. 1993 Feb;60(2):765-7. | ||||
REF 229 | Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors. Mol Pharmacol. 1994 Feb;45(2):330-4. | ||||
REF 230 | [6-O-methyl-11C]Diprenorphine, Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013. 2006 May 24 [updated 2007 May 12]. | ||||
REF 231 | Mu opioid receptor antagonists: recent developments. ChemMedChem. 2007 Nov;2(11):1552-70. | ||||
REF 232 | OxyContin abuse and overdose. Postgrad Med. 2009 Mar;121(2):163-7. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.